长春氟宁药代动力学变异及暴露-毒性关系的综合特征分析:来自18项试验的研究
该研究整合18项I期和II期试验的长春氟宁浓度与安全性数据,采用四室群体PK模型和半生理PK/PD模型分析。结果显示长春氟宁清除率可由肌酐清除率、体表面积及联合聚乙二醇脂质体多柔比星解释,个体间变异从28.2%降至25.3%;剂量降低较延迟给药可降低第2周期3-4级中性粒细胞减少风险。
要点
- 长春氟宁清除率受肌酐清除率、体表面积及联合PEG化多柔比星影响。
- 剂量降低较延迟给药可降低第2周期3-4级中性粒细胞减少风险。
- 中度肾功能不全患者320 mg/m²每4周一次较280 mg/m²每3周一次中性粒细胞减少风险更高(42.1% vs 23.3%)。
核心结论
- 首次提出长春氟宁静脉给药的全局综合临床药理学分析,可能有助于指导剂量调整。
研究设计与样本
- 基于18项I期和II期研究的长春氟宁浓度与安全性数据,使用Nonmem进行群体PK和PK/PD分析。
- 采用四室模型描述长春氟宁PK并测试协变量解释个体间变异。
- 采用半生理群体PK/PD模型描述给药后绝对中性粒细胞计数(ANC)的时间进程。
- 采用逻辑回归模型检验长春氟宁暴露与毒性之间的关系。
主要发现
- 长春氟宁清除率由肌酐清除率、体表面积及联合聚乙二醇脂质体多柔比星解释,个体间变异从28.2%降至25.3%。
- 模拟显示长春氟宁剂量降低时,第2周期3-4级中性粒细胞减少风险始终低于延迟给药。
- 中度肾功能不全患者,长春氟宁320 mg/m²每4周一次时3-4级中性粒细胞减少风险为42.1%,280 mg/m²每3周一次时为23.3%。
临床怎么用
- 临床可根据肌酐清除率、体表面积及是否联合聚乙二醇脂质体多柔比星评估长春氟宁个体间变异。
- 对于需调整剂量的患者,降低剂量可能较延迟给药更能降低第2周期3-4级中性粒细胞减少风险。
- 中度肾功能不全患者可参考320 mg/m²每4周一次与280 mg/m²每3周一次的中性粒细胞减少风险差异进行剂量决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Vinflunine is a novel tubulin-targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum-based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and phase II studies. However, no global pharmacometric analysis had been conducted as yet. METHODS: Vinflunine concentrations and safety data from 18 phase I and phase II studies were used to conduct population PK and PK/PD analysis, using Nonmem. A four-compartment model was used to describe vinflunine PK and several covariates were tested to explain interindividual variability. In terms of PK/PD relationship, a semiphysiological population PK/PD model was applied to describe time course of absolute neutrophil counts (ANC) after vinflunine administration and logistic regression models were used to test the relationship between vinflunine exposure and toxicities. RESULTS: Vinflunine clearance is explained by creatinine clearance, body surface area and combination with PEGylated doxorubicin, leading to a decrease from 28.2 to 25.3% of the interindividual variability. When vinflunine dose is decreased, simulations of ANC time course (via a semiphysiological model) after vinflunine administration show a risk of neutropenia grade 3-4 at cycle 2 always lower than when dose is delayed. As an example, for moderate renal impaired patients, the risk is 42.1% when vinflunine is dosed at 320 mg m-2 once every 4 weeks vs. 23.3% for 280 mg m-2 once every 3 weeks. CONCLUSIONS: We propose for the first time a global comprehensive clinical pharmacological analysis for intravenous vinflunine that may help drive dose adjustment.
引用
- Schmitt A, Nguyen L, Zorza G, et al. Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials. Br J Clin Pharmacol. 2018. PMID: 29341179. doi:10.1111/bcp.13518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。